Prospective Grant of an Exclusive Patent License: Use of Tomentosenol in Treating or Preventing Skin Disorders, 62190 [2021-24445]
Download as PDF
<![CDATA[
62190
Federal Register / Vol. 86, No. 214 / Tuesday, November 9, 2021 / Notices
Name of Committee: Division of Intramural
Research Board of Scientific Counselors,
NIAID.
Date: December 13–15, 2021.
Time: 8:30 a.m. to 11:15 a.m.
Agenda: To review and evaluate personnel
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health, 50
Center Drive, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Laurie Lewellen,
Committee Manger, Division of Intramural
Research Program Support Staff, National
Institute of Allergy and Infectious Diseases,
National Institutes of Health, Building 33,
Room 1N24, 33 North Drive, Bethesda, MD
20892, 301–761–6362, Laurie.Lewallen@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: November 3, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–24443 Filed 11–8–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Use of Tomentosenol
in Treating or Preventing Skin
Disorders
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an exclusive, sublicensable
patent license to University of the
Sunshine Coast (‘‘USC’’), a public
university based on the Sunshine Coast,
Queensland, Australia, in its rights to
the inventions and patents listed in the
SUPPLEMENTARY INFORMATION section of
this notice.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before November 24, 2021 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Rose M. Freel, Ph.D., Senior
Licensing and Patenting Manager, NCI
Technology Transfer Center, Telephone
jspears on DSK121TN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:00 Nov 08, 2021
Jkt 256001
(301) 624–8775 or Email: rose.freel@
nih.gov.
The
following and all continuing U.S. and
foreign patents/patent applications
thereof are the intellectual properties to
be licensed under the prospective
agreement to USC: Australian
Provisional Patent Application No.
2021902329, filed Aug 3, 2021, entitled
‘‘Use of tomentosenol in treating or
preventing skin disorders’’ (HHS Ref.
No. E–107–2021–0).
The patent rights in these inventions
have been assigned to the Government
of the United States of America and the
University of the Sunshine Coast. The
prospective patent license will be for
the purpose of consolidating the patent
rights to USC, one of the co-owners of
said rights, for commercial development
and marketing. Consolidation of these
co-owned rights is intended to expedite
development of the invention,
consistent with the goals of the BayhDole Act codified as 35 U.S.C. 200–212.
The prospective patent license will be
worldwide, exclusive, and may be
limited to those fields of use
commensurate in scope with the patent
rights. It will be sublicensable, and any
sublicenses granted by USC will be
subject to the provisions of 37 CFR part
401 and 404.
The invention pertains to
tomentosenol A, a natural product that
may be useful for treating, inhibiting, or
preventing scar formation development
or progression, reducing pre-existing
scar tissue, and/or other fibrotic skin
disorders. Based on current available
data, the intended use for the invention
is as a therapeutic in scar therapy, skin
fibrosis, skin diseases, and inhibition of
the proliferation or migration of skin
cells.
This notice is made pursuant to 35
U.S.C. 209 and 37 CFR part 404. The
prospective exclusive patent license
will include terms for the sharing of
royalty income with NCI from
commercial sublicenses of the patent
rights and may be granted unless within
fifteen (15) days from the date of this
published notice the NCI receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license
that are timely filed in response to this
notice will be treated as objections to
the grant of the contemplated exclusive
patent license. In response to this
Notice, the public may file comments or
objections. Comments and objections,
other than those in the form of a license
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information from these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: November 3, 2021.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2021–24445 Filed 11–8–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Library of Medicine; Notice of
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Board of Regents of the
National Library of Medicine.
The meeting will be open to the
public as indicated below. Individuals
who plan to attend and need special
assistance, such as sign language
interpretation or other reasonable
accommodations should notify the
Contact Person listed below in advance
of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Regents of
the National Library of Medicine.
Date: February 8, 2022.
Open: February 8, 2022, 10:00 a.m. to 3:30
p.m.
Agenda: Program Discussion.
Place: Virtual Meeting.
Closed: February 8, 2022, 3:30 p.m. to 4:00
p.m.
Agenda: To review and evaluate grant
applications.
Contact Person: Christine Ireland,
Committee Management Officer, Division of
Extramural Programs, National Library of
Medicine, 6705 Rockledge Drive, Suite 500,
Bethesda, MD 20892, 301–594–4929,
irelanc@mail.nih.gov.
E:\FR\FM\09NON1.SGM
09NON1
]]>Agencies
[Federal Register Volume 86, Number 214 (Tuesday, November 9, 2021)]
[Notices]
[Page 62190]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-24445]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Use of
Tomentosenol in Treating or Preventing Skin Disorders
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute, an institute of the National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an exclusive, sublicensable patent license
to University of the Sunshine Coast (``USC''), a public university
based on the Sunshine Coast, Queensland, Australia, in its rights to
the inventions and patents listed in the SUPPLEMENTARY INFORMATION
section of this notice.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before November 24, 2021 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated an Exclusive Patent License
should be directed to: Rose M. Freel, Ph.D., Senior Licensing and
Patenting Manager, NCI Technology Transfer Center, Telephone (301) 624-
8775 or Email: [email protected].
SUPPLEMENTARY INFORMATION: The following and all continuing U.S. and
foreign patents/patent applications thereof are the intellectual
properties to be licensed under the prospective agreement to USC:
Australian Provisional Patent Application No. 2021902329, filed Aug 3,
2021, entitled ``Use of tomentosenol in treating or preventing skin
disorders'' (HHS Ref. No. E-107-2021-0).
The patent rights in these inventions have been assigned to the
Government of the United States of America and the University of the
Sunshine Coast. The prospective patent license will be for the purpose
of consolidating the patent rights to USC, one of the co-owners of said
rights, for commercial development and marketing. Consolidation of
these co-owned rights is intended to expedite development of the
invention, consistent with the goals of the Bayh-Dole Act codified as
35 U.S.C. 200-212.
The prospective patent license will be worldwide, exclusive, and
may be limited to those fields of use commensurate in scope with the
patent rights. It will be sublicensable, and any sublicenses granted by
USC will be subject to the provisions of 37 CFR part 401 and 404.
The invention pertains to tomentosenol A, a natural product that
may be useful for treating, inhibiting, or preventing scar formation
development or progression, reducing pre-existing scar tissue, and/or
other fibrotic skin disorders. Based on current available data, the
intended use for the invention is as a therapeutic in scar therapy,
skin fibrosis, skin diseases, and inhibition of the proliferation or
migration of skin cells.
This notice is made pursuant to 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive patent license will include terms for the
sharing of royalty income with NCI from commercial sublicenses of the
patent rights and may be granted unless within fifteen (15) days from
the date of this published notice the NCI receives written evidence and
argument that establishes that the grant of the license would not be
consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license that are timely filed in
response to this notice will be treated as objections to the grant of
the contemplated exclusive patent license. In response to this Notice,
the public may file comments or objections. Comments and objections,
other than those in the form of a license application, will not be
treated confidentially, and may be made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information from these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: November 3, 2021.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2021-24445 Filed 11-8-21; 8:45 am]
BILLING CODE 4140-01-P
